Targeting autophagy with natural products to prevent SARS-CoV-2 infection

被引:23
|
作者
Vidoni, Chiara [1 ]
Fuzimoto, Andrea [2 ]
Ferraresi, Alessandra [1 ]
Isidoro, Ciro [1 ]
机构
[1] Univ Piemonte Orientale, Dept Hlth Sci, Novara, Italy
[2] Holist Sync, Holist Integrat Med, Washington, DC USA
来源
关键词
COVID-19; Virophagy; Coronavirus; Chloroquine; Pandemic; Phytotherapy; Resveratrol; MOLECULAR-DYNAMICS; ANTIVIRAL ACTION; ARTEMISIA-ANNUA; IN-VITRO; VIRUS; REPLICATION; BAICALIN; CORONAVIRUSES; PROCYANIDIN; INHIBITION;
D O I
10.1016/j.jtcme.2021.10.003
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Autophagy is a catabolic process that maintains internal homeostasis and energy balance through the lysosomal degradation of redundant or damaged cellular components. During virus infection, autophagy is triggered both in parenchymal and in immune cells with different finalistic objectives: in parenchymal cells, the goal is to destroy the virion particle while in macrophages and dendritic cells the goal is to expose virion-derived fragments for priming the lymphocytes and initiate the immune response. However, some viruses have developed a strategy to subvert the autophagy machinery to escape the destructive destiny and instead exploit it for virion assembly and exocytosis. Coronaviruses (like SARS-CoV-2) possess such ability. The autophagy process requires a set of proteins that constitute the core machinery and is controlled by several signaling pathways. Here, we report on natural products capable of interfering with SARS-CoV-2 cellular infection and replication through their action on autophagy. The present study provides support to the use of such natural products as adjuvant therapeutics for the management of COVID-19 pandemic to prevent the virus infection and replication, and so mitigating the progression of the disease. (c) 2021 Center for Food and Biomolecules, National Taiwan University. Production and hosting by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).
引用
收藏
页码:55 / 68
页数:14
相关论文
共 50 条
  • [31] Natural SARS-CoV-2 infection in two cats in Spain
    Cano-Gomez, C.
    Perez-Ramirez, E.
    Aguilera-Sepulveda, P.
    Llorente, F.
    Villalba, A.
    Jimenez-Clavero, M. A.
    Fernandez-Pinero, J.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2022, 116 : S70 - S70
  • [32] Natural SARS-CoV-2 Infection in Kept Ferrets, Spain
    Gortazar, Christian
    Barroso-Arevalo, Sandra
    Ferreras-Colino, Elisa
    Isla, Julio
    de la Fuente, Gabriela
    Rivera, Belen
    Dominguez, Lucas
    de la Fuente, Jose
    Sanchez-Vizcaino, Jose M.
    EMERGING INFECTIOUS DISEASES, 2021, 27 (07) : 1994 - 1996
  • [33] Natural killer cell exhaustion in SARS-CoV-2 infection
    Gallardo-Zapata, Janet
    Maldonado-Bernal, Carmen
    INNATE IMMUNITY, 2022, 28 (06) : 189 - 198
  • [34] Characterisation and natural progression of SARS-CoV-2 infection in ferrets
    Au, Gough G.
    Marsh, Glenn A.
    McAuley, Alexander J.
    Lowther, Suzanne
    Trinidad, Lee
    Edwards, Sarah
    Todd, Shawn
    Barr, Jennifer
    Bruce, Matthew P.
    Poole, Timothy B.
    Brown, Sheree
    Layton, Rachel
    Riddell, Sarah
    Rowe, Brenton
    Soldani, Elisha
    Suen, Willy W.
    Bergfeld, Jemma
    Bingham, John
    Payne, Jean
    Durr, Peter A.
    Drew, Trevor W.
    Vasan, Seshadri S.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [35] Targeting papain-like protease by natural products as novel therapeutic potential SARS-CoV-2
    Waqas, Muhammad
    Ullah, Saeed
    Halim, Sobia Ahsan
    Rehman, Najeeb Ur
    Ali, Amjad
    Jan, Afnan
    Bin Muhsinah, Abdullatif
    Khan, Ajmal
    Al-Harrasi, Ahmed
    INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES, 2024, 258
  • [36] In-Silico targeting of SARS-CoV-2 NSP6 for drug and natural products repurposing
    Abdelkader, Ahmed
    Elzemrany, Amal A.
    El-Nadi, Mennatullah
    Elsabbagh, Sherif A.
    Shehata, Moustafa A.
    Eldehna, Wagdy M.
    El-Hadidi, Mohamed
    Ibrahim, Tamer M.
    VIROLOGY, 2022, 573 : 96 - 110
  • [37] The dynamics of antibodies to SARS-CoV-2 in a case of SARS-CoV-2 infection
    Xia, Yong
    Hong, Honghai
    Feng, Yao
    Liu, Meiling
    Pan, Xingfei
    Chen, Dexiong
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 96 : 359 - 360
  • [38] XNAzymes targeting the SARS-CoV-2 genome inhibit viral infection
    Pehuén Pereyra Gerber
    Maria J. Donde
    Nicholas J. Matheson
    Alexander I. Taylor
    Nature Communications, 13
  • [39] Targeting Microbiome: An Alternative Strategy for Fighting SARS-CoV-2 Infection
    Spagnolello, Ornella
    Pinacchio, Claudia
    Santinelli, Letizia
    Vassalini, Paolo
    Innocenti, Giuseppe Pietro
    De Girolamo, Gabriella
    Fabris, Silvia
    Giovanetti, Marta
    Angeletti, Silvia
    Russo, Alessandro
    Mastroianni, Claudio M.
    Ciccozzi, Massimo
    Ceccarelli, Giancarlo
    d'Ettorre, Gabriella
    CHEMOTHERAPY, 2021, 66 (1-2) : 24 - 32
  • [40] Pharmacological therapies and drug development targeting SARS-CoV-2 infection
    Jiang, Yizhou
    Rubin, Limor
    Zhou, Zhiwei
    Zhang, Haibo
    Su, Qiaozhu
    Hou, Sheng-Tao
    Lazarovici, Philip
    Zheng, Wenhua
    CYTOKINE & GROWTH FACTOR REVIEWS, 2022, 68 : 13 - 24